Analysis of gene expression profile microarray data in complex regional pain syndrome
- Authors:
- Published online on: July 12, 2017 https://doi.org/10.3892/mmr.2017.6950
- Pages: 3371-3378
Abstract
Introduction
Complex regional pain syndrome (CRPS) is an uncommon chronic pain condition that develops following trauma. The features include limb pain, allodynia, hypersensitivity, motor abnormality and trophic alterations (1). Women are affected more commonly than men, and postmenopausal women demonstrate the highest risk (2). CRPS is classified into two subtypes depending on the presence of peripheral nerve injury. CRPS type I without peripheral nerve injury is more common than type II, which presents as peripheral nerve injury (3). In addition, CRPS is categorized into ‘warm’ or ‘cold’ CRPS depending on whether skin temperature is increased or decreased (4). Although CRPS is designated as an orphan disease in the general population, it affects ~4–7% patients experiencing limb fractures (5). CRPS is a burden on the healthcare system and society. A number of different therapeutic strategies have been applied to treat CRPS, including pharmacological, interventional and psychological methods; however, there evidence to support their efficiency of these methods is insufficient (5). The pathogenesis of CRPS is unclear (6), however several mechanisms have are thought to be involved, including inflammation, neurogenic inflammation and alterations of the central nerve system (6). Goebel et al (7) elucidated the association between inflammation, immune response and CRPS, and an autoimmune model was proposed. Oaklander et al (8) proposed that CRPS is associated with distal degeneration of small diameter peripheral axons. Barad et al (9) demonstrated that brain structure was involved in CRPS. However, little is known about how these mechanisms interact to lead to CRPS. Therefore, identifying key genes or signaling pathways involved in the development of CRPS may facilitate elucidation of the integrated mechanism of CRPS and enable the development of targeted therapies.
Genome-wide expression profiling of CPRS was recently performed by Jin et al (10). The authors collected and analyzed peripheral blood examples from healthy controls and patients with CRPS. Differentially expressed genes (DEGs) were identified using microarray analysis, and out of those identified, 6 genes were selected for further confirmation by reverse transcription-quantitative polymerase chain reaction analysis. The authors focused on a significantly upregulated DEG (matrix metallopeptidase 9), thought to be associated with pain progression in CRPS. However, the gene/protein interaction networks involved in CRPS remain unknown, which is necessary to elucidate how inflammation, neurogenic inflammation and alterations of the central nervous system are involved in CRPS. Therefore, the authors of the present study constructed a protein-protein interaction network in order to identify the specific molecular interactions involved in CRPS.
In the present study, the GSE47603 gene expression profiling microarray data deposited by Jin et al (10) was obtained and used to identify CRPS-associated genes in patients with CRPS. The microarray data was used to identify key DEGs associated with CRPS by employing comprehensive analysis methods in order to enrich the functions and signaling pathways of identified DEGs. In addition, a protein-protein interaction (PPI) network was constructed and analyzed to identify hub genes. The aim of the current study was to identify several key genes associated with the disease, and examine their potential function in the development of CRPS by expression profile analysis. The results may facilitate the identification of potential targets for the diagnosis and treatment of CRPS.
Materials and methods
Microarray data
The GSE47603 microarray data, deposited by Jin et al (10) was obtained from the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo). This microarray used the GPL10558 platform (Illumina HumanHT-12 v4 expression beadchip; Illumina, Inc., San Diego, CA, USA). A total of 9 peripheral blood samples from 4 patients with CRPS and 5 healthy controls were included in the genome-wide expression profiling array, as described previously (10). Out of the patients with CRPS, 2 patients presented with CRPS type I and 2 patients presented with CRPS type II. Patients who received medication of CRPS were included; however, those with additional neurogenic disorders caused by this medication were excluded. The control subjects did not present with infectious disease, pain disorders and had not undergone recent surgery.
Data processing
Array data export, processing and analysis was performed using the Gene Expression Module (version, 1.9.0) of Illumina GenomeStudio software (version, 2011.1; Illumina, Inc.). Data were already quantile-normalized. Significant DEGs were identified by comparing profile data from patients with CRPS with that of control subjects using the online analysis tool, GEO2R (http://www.ncbi.nlm.nih.gov/geo/geo2r/, version R 3.2.3, Biobase 2.30.0, GEOquery 2.40.0, limma 3.26.8), as was accessible from the GEO website. This tool uses the linear models for microarray analysis package to identify DEGs and provides t-statistics and P-values. Benjamini and Hochberg's false discovery rate was applied to adjust the P-values. DEGs with adjusted P-values of <0.05 and fold change (FC) values of >1.5 were considered to be significant.
Gene ontology (GO) enrichment and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis
The GO database (http://geneontology.org) is a large-scale collection of genomic data divided into 3 categories according to biological process (BP), molecular function and cellular component. KEGG (http://www.genome/ad.jp/kegg/) is a pathway-associated database for gene classification. The Database for Annotation Visualization and Integrated Discovery (DAVID, https://david.ncifcrf.gov/) integrates biological data and analysis tools to provide systematic functional annotation for a large number of genes and proteins.
To analyze the putative functions of identified DEGs, GO annotation associated with BP and KEGG pathway enrichment analyses were performed using the online DAVID tool version 6.7 (11,12). A P-value of <0.05 and gene counts of >2 were considered to be significant.
PPI construction
The Search Tool for the Retrieval of Interaction Genes (STRING; http://string.embl.de/) database collects comprehensive information regarding predicted and experimental interactions between proteins in a given cell. In the present study, DEGs were mapped in the STRING database version, 10.0 (13) to construct a PPI network, which provides an improved understanding of the functional organization of the proteome. A combined score of >4 was set as the threshold. The PPI network was subsequently analyzed using Cytoscape (http://www.cytoscape.org/, version, 3.3.0) software. The degree of connectivity of each node in the PPI network was calculated, and the hub nodes were identified. Genes were clustered using the MCODE Cytoscape plugin (version, 1.4.1).
Results
DEG analysis
Using adjusted P-values of <0.05 and FC values of >1.5, a total of 257 DEGs were identified in blood samples from patients with CRPS when compared with the controls. This included 243 upregulated and 14 downregulated genes (Tables I and II). The most significantly upregulated and downregulated genes were human leukocyte antigen (HLA)-DRB1 and HLA-DQB1, respectively, which belong to the HLA family. An additional member of the HLA family, HLA-DRB4, was significantly downregulated in CRPS samples when compared with controls (Table II).
Functional enrichment analysis
The over-represented GO-BP terms of DEGs were primarily associated with antigen processing and presentation, the immune response process, the integrin-mediated signaling pathway, cell motion and adhesion, angiogenesis, and cell-substrate junction assembly (Table III). In addition, DEGs were enriched in KEGG pathways including viral myocarditis, systemic lupus erythematosus, asthma, allograft rejection, graft-vs.-host disease, type I diabetes mellitus, intestinal immune network for immunoglobulin A production, autoimmune thyroid disease, antigen processing and presentation and hematopoietic cell lineage (Table IV).
Table III.Most significant GO-biological process terms enriched by differentially expressed genes (n=15). |
PPI analysis
The PPI network generated using the STRING database included 155 nodes and 400 edges (Fig. 1). Topological structure analysis performed by Cytoscape software revealed the degree of genes in the PPI network. Nodes with a higher degree are more connected with other nodes, and they are considered to contribute to the stability of the network and are designated as hub nodes. In the present study, genes with a higher degree included adenovirus early region 1A binding protein p300 (EP300), CREB-binding protein (CREBBP), signal transducer and activator of transcription (STAT)3 and STAT5A of the STAT protein family, interleukin 8 (IL8) and integrin α M (ITGAM).
A total of 3 modules with a score of >4 were identified using the MCODE plugin (Fig. 2). Cluster 1 exhibited the highest score, and DEGs, such as EP300, CREBBP, STAT3, STAT5A and ITGAM were included. Enrichment analysis demonstrated that the GO-BP terms enriched by these genes were associated with regulation of transcription, biosynthesis, hormone stimuli responses and cell differentiation (Table V). DEGs in cluster 2 primarily included ITGAM, retinoic acid receptor α, integrin subunit α 2B and DNA-directed RNA polymerase II subunit RPB1 (Fig. 2), which were enriched in GO-BP terms associated with cell adhesion and apoptosis (Table V). DEGs in cluster 3 included C5 anaphylatoxin chemotactic receptor 1, GPR18, hydroxycarboxylic acid receptor (HCAR) 2 and HCAR3 (Fig. 2), which were enriched in the G-protein signaling pathway (Table V).
Table V.Significant GO-biological process terms enriched by differentially expressed genes in clusters. |
Discussion
In the present study, a total of 257 DEGs were identified in blood samples from patients with CRPS when compared with healthy controls. Pathway enrichment analysis demonstrated that the identified DEGs were primarily enriched in immune response, cell motion, adhesion and angiogenesis signaling pathways. In the PPI network, EP300 displayed the highest degree and was present in cluster 1. Additional DEGs in cluster 1 with relatively high degrees were STAT3, CREBBP, STAT5A, ITGAM, notch homolog 1, CCAAT/enhancer binding protein β and mitogen-activated protein kinase 3.
Goebel et al (14) demonstrated that intravenous immunoglobulin (IVIG) is effective for the reduction of pain in patients with CRPS, which suggests that the immune response may be important in the development of CRPS. Subsequent studies indicated that neuroautoimmunity and neurogenic inflammation contribute to CRPS. Cooper et al (15) demonstrated that infiltrating leukocytes reacted to autoantibodies that bind to autoantigens located on the surface of neuronal and glial cell targets, and were closely associated with neuroautoimmune responses. In addition, the development of autoantibodies against the β2 adrenergic receptor and muscarinic-2 receptor were identified in patients with CRPS (16).
HLA-DQB1, HLA-DRB4 and HLA-DRB1, which belong to class II of the HLA family, are expressed by a subgroup of immune cells, including B cells, activated T cells and macrophages (17). Kemler et al (18) discovered increased expression of HLA-DQB1 among CRPS patients. In addition, a previous study demonstrated that HLA is associated with CRPS whereby two members of the HLA family (HLA-DQ8 and HLA-B62) were observed to be differentially expressed in different subtypes of CRPS (19). Furthermore, genes in class I of the HLA family were observed to be associated with the development of CRPS (20). HLA-DR2 and HLA-DR13 have been reported to be associated with CRPS (21,22). However, studies in HLA-DRB4 and DRB1 have not focused on their roles in CRPS. Therefore, further research to determine how HLA may be involved in CRPS may provide additional important information. Changes in the expression levels of the HLA family indicates that CRPS may be associated with inflammation regulation (19). Additionally, CRPS may be important to genes closely associated with HLA instead of HLA genes themselves (20).
EP300 and its paralog CREBBP are transcriptional coactivators that regulate gene transcription by connecting DNA-binding and transcription factors, relaxing chromatin through its intrinsic histone acetyltransferase activity and modifying specific transcription factors (23). EP300 and CREBBP have been implicated in a large number of diseases. Lunning et al (24) demonstrated that mutations in EP300 and CREBBP are present in germinal center B-cell lymphomas. Kishimoto et al (25) demonstrated that EP300 and CREBBP may be involved in the pathogenesis of follicular lymphoma. Notably, Seltzer et al (26) indicated that EP300 and CREBBP were associated with postnatal microcephaly. That EP300 and CREBBP have a high degree in the PPI network found by our study may add to the myriad of roles of EP300 and CREBBP in disease.
STAT3 and STAT5 belong to the STAT protein family, which was first discovered as part of the cytokine signaling pathway (27). These proteins demonstrate a significant effect on the immune response and in the process of oncogenesis (27). STAT3A serves multiple roles in cytokine signaling pathways (27). STAT3-knock out mice were incapable of completing gastrulation (28), and conditional STAT3-knock out promotes apoptosis (29). In addition, STAT3 is involved in the differentiation of CD4+ cells to Th17 cells, which protect against invading bacteria and fungi and are involved in the autoimmune response (30,31). Furthermore, STAT3 is a recognized oncogene (32). Similarly, STAT5 serves an important role in the differentiation of CD4+ cells into Treg cells, which are involved in reducing the immune response and protecting against autoimmune disease (31,33). STAT5 expression deficiency was found to closely associated with tumorigenesis by changing the function of natural killer cells to tumor promotion (34). This implies that STAT may be the potential therapeutic target for CRPS (31).
In conclusion, the results of the present study provided additional evidence in support of the hypothesis that neuroautoimmunity is an important factor for the pathogenesis of CRPS. And significant genes such as HLA-DQB1, HLA-DRB4, HLA-DRB1 from the HLA family, EP300 and its paralog CREBBP, STAT3 and STAT5 from the STAT family were identified by differentially expressed gene and topological analyses, and module identification of the PPI network constructed from these genes. However, further experiments such as western blotting are required to confirm the changes of expression levels of these genes. Additionally, to fully elucidate the mechanism behind how change in the expression levels of these genes lead to CRPS, further studies are required to determine, which pathways contribute to CRPS. Due to the small sample size of the present study the current findings are limited. Therefore, pooling CRPS samples from different sources in future investigations will increase the sample size and confirm the current findings.
References
Palmer G: Complex regional pain syndrome. Aust Prescr. 38:82–86. 2015. View Article : Google Scholar : PubMed/NCBI | |
de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH and Sturkenboom MC: The incidence of complex regional pain syndrome: A population-based study. Pain. 129:12–20. 2007. View Article : Google Scholar : PubMed/NCBI | |
Stanton-Hicks M, Jänig W, Hassenbusch S, Haddox JD, Boas R and Wilson P: Reflex sympathetic dystrophy: Changing concepts and taxonomy. Pain. 63:127–133. 1995. View Article : Google Scholar : PubMed/NCBI | |
Bruggeman AW, Oerlemans MH and Frölke JP: Warm and cold complex regional pain syndromes: Differences beyond skin temperature? Neurology. 73:1711–1712. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bruehl S: Complex regional pain syndrome. BMJ. 351:h27302015. View Article : Google Scholar : PubMed/NCBI | |
Bussa M, Guttilla D, Lucia M, Mascaro A and Rinaldi S: Complex regional pain syndrome type I: A comprehensive review. Acta Anaesthesiol Scand. 59:685–697. 2015. View Article : Google Scholar : PubMed/NCBI | |
Goebel A and Blaes F: Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev. 12:682–686. 2013. View Article : Google Scholar : PubMed/NCBI | |
Oaklander AL and Fields HL: Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? Ann Neurol. 65:629–638. 2009. View Article : Google Scholar : PubMed/NCBI | |
Barad MJ, Ueno T, Younger J, Chatterjee N and Mackey S: Complex regional pain syndrome is associated with structural abnormalities in pain-related regions of the human brain. J Pain. 15:197–203. 2014. View Article : Google Scholar : PubMed/NCBI | |
Jin EH, Zhang E, Ko Y, Sim WS, Moon DE, Yoon KJ, Hong JH and Lee WH: Genome-wide expression profiling of complex regional pain syndrome. PLoS One. 8:e794352013. View Article : Google Scholar : PubMed/NCBI | |
Huang DW, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID Bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI | |
da Huang W, Sherman BT and Lempicki RA: Bioinfromatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI | |
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI | |
Goebel A: Immunoglobulin responsive chronic pain. J Clin Immunol. 30:(Suppl 1). S103–S108. 2010. View Article : Google Scholar : PubMed/NCBI | |
Cooper MS and Clark VP: Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome. J Neuroimmune Pharmacol. 8:452–469. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kohr D, Singh P, Tschernatsch M, Kaps M, Pouokam E, Diener M, Kummer W, Birklein F, Vincent A, Goebel A, et al: Autoimmunity against the β\2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain. 152:2690–2700. 2011. View Article : Google Scholar : PubMed/NCBI | |
Klein J and Sato A: The HLA system. First of two parts. N Engl J Med. 343:702–709. 2000. View Article : Google Scholar : PubMed/NCBI | |
Kemler MA, van de Vusse AC, van den Berg-Loonen EM, Barendse GA, van Kleef M and Weber WE: HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology. 53:1350–1351. 1999. View Article : Google Scholar : PubMed/NCBI | |
van Rooijen DE, Roelen DL, Verduijn W, Haasnoot GW, Huygen FJ, Perez RS, Perez RS, Claas FH, Marinus J, van Hilten JJ and van den Maagdenberg AM: Genetic HLA associations in complex regional pain syndrome with and without dystonia. J Pain. 13:784–789. 2012. View Article : Google Scholar : PubMed/NCBI | |
van de Beek WJ, Roep BO, van der Slik AR, Giphart MJ and van Hilten BJ: Susceptibility loci for complex regional pain syndrome. Pain. 103:93–97. 2003. View Article : Google Scholar : PubMed/NCBI | |
Mailis A and Wade J: Profile of Caucasian women with possible genetic predisposition to reflex sympathetic dystrophy: A pilot study. Clin J Pain. 10:210–217. 1994. View Article : Google Scholar : PubMed/NCBI | |
van Hilten JJ, van de Beek WJ and Roep BO: Multifocal or generalized tonic dystonia of complex regional pain syndrome: A distinct clinical entity associated with HLA-DR13. Ann Neurol. 48:113–116. 2000. View Article : Google Scholar : PubMed/NCBI | |
Wang F, Marshall CB and Ikura M: Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: Structural and functional versatility in target recognition. Cell Mol Life Sci. 70:3989–4008. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lunning MA and Green MR: Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. Blood Cancer J. 5:e3612015. View Article : Google Scholar : PubMed/NCBI | |
Kishimoto W and Nishikori M: Molecular pathogenesis of follicular lymphoma. J Clin Exp Hematop. 54:23–30. 2014. View Article : Google Scholar : PubMed/NCBI | |
Seltzer LE and Paciorkowski AR: Genetic disorders associated with postnatal microcephaly. Am J Med Genet C Semin Med Genet. 166C:140–155. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lim CP and Cao X: Structure, function, and regulation of STAT proteins. Mol Biosyst. 2:536–550. 2006. View Article : Google Scholar : PubMed/NCBI | |
Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T and Akira S: Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA. 94:3801–3804. 1997. View Article : Google Scholar : PubMed/NCBI | |
Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T and Akira S: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J Immunol. 161:4652–4660. 1998.PubMed/NCBI | |
Laurence A and O'Shea JJ: T(H)-17 differentiation: Of mice and men. Nat Immunol. 8:903–905. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ross JA, Nagy ZS, Cheng H, Stepkowski SM and Kirken RA: Regulation of T cell homeostasis by JAKs and STATs. Arch Immunol Ther Exp (Warsz). 55:231–245. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI | |
Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, et al: Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood. 109:4368–4375. 2007. View Article : Google Scholar : PubMed/NCBI | |
Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, et al: STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion. Cancer Discov. 6:414–429. 2016. View Article : Google Scholar : PubMed/NCBI |